Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
$1.48
-$0.09(-19.80%)
At close: 4:00 PM EST
$1.48
-$0.09(-19.80%)
Day’s Range― - ―
52-Week Range$1.17 - $8.08
Previous CloseN/A
Volume1.10M
Average Volume (3M)1.58M
Market Cap
$32.37M
Enterprise Value$104.33M
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$109.29M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,869,492
10 Day Avg. Volume1,230,633
30 Day Avg. Volume1,584,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)6.69
P/FCF Ratio-0.21
Enterprise Value/Market Cap3.22
Enterprise Value/Revenue138.74
Enterprise Value/Gross Profit-363.53
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$3.50Price Target Upside136.49% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-3.02
Revenue Forecast (FY)$1.57M
Bulls Say, Bears Say
Bulls Say
Clinical Endpoint ValidationStrong correlation between clinician assessments and patient or caregiver-rated outcomes supports using the mCGI-S measure to demonstrate outpatient efficacy for a label extension.
Market OpportunityAbsence of any FDA-approved therapies for acute at-home agitation combined with favorable SERENITY At-Home results could position the product as the first approved treatment in the at-home setting.
Regulatory SubmissionCompletion of all clinical trials required for the supplemental New Drug Application supports progression toward regulatory review for an at-home indication.
Bears Say
Operational And Financing RiskProlonged trial timelines may elevate development costs and heighten the need for additional financing, which could pressure the company's valuation and execution flexibility.
Pipeline ConcentrationDelays or setbacks in BXCL701 would increase dependence on BXCL501 for near-term progress, amplifying clinical and commercial uncertainty for the pipeline.
Trial DelaysRisk of delays in completing BXCL501 and BXCL701 clinical trials could push back regulatory review and defer potential commercialization timelines.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $8.08 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $32.37M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is May 11, 2026 which is in 63 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 21,869,492 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Currently, no hedge funds are holding shares in BTAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (136.49% Upside)
$3.50 (136.49% Upside)
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 43%
Bearish news 57%
Bearish news 57%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.59%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BTAI Stock 12 Month Forecast
Average Price Target
$3.50
▲(136.49% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Kezar Life Sciences
―
Annovis Bio
―
BioAtla
―
Century Therapeutics
―
Ownership Overview
3.61% Insiders
1.67% Mutual Funds
0.13% Other Institutional Investors
93.65% Public Companies and
Individual Investors